Overview of Antinol

Property	Description
Active Ingredient	Disulfiram (INN)
Form	Oral Tablets (often scored)
Pharmacological Class	Alcohol Deterrent Agent, Aldehyde Dehydrogenase Inhibitor
General Purpose	Support for abstinence in Alcohol Use Disorder
Origin	Synthetic Compound

Antinol (Disulfiram): Definition and Pharmacological Classification

Disulfiram is a single-ingredient, synthetic prescription medication classified as an Alcohol Deterrent Agent for use in the treatment of chronic alcohol dependence. This agent is clinically recognized for its ability to create an active, physiological barrier to ethanol consumption. The drug’s core function is to establish a chemical barrier that provides a deterrent against alcohol consumption. It is specifically utilized as an adjunct to psychosocial treatment to support a patient’s commitment to achieving and maintaining absolute abstinence from alcohol, particularly in adult patients demonstrating high motivation for recovery.

Composition, Form, and General Purpose

The medication contains Disulfiram (INN) as the sole active ingredient and is primarily supplied as Oral Tablets, often manufactured with a score to facilitate precise administration. The general purpose of administering Disulfiram is to support individuals dealing with Alcohol Use Disorder by creating a definitive chemical consequence for drinking. Disulfiram maintains an established role as a medication for supporting abstinence in chronic alcoholism. Its differentiating factor lies in its unique pharmacological profile, which provides a non-craving-based mechanism of action that complements other approaches, reinforcing the therapeutic goal of long-term sobriety.

Mechanism of Action (High-Level Principle)

The mechanism of Disulfiram involves acting as an Aldehyde Dehydrogenase Inhibitor, which means it blocks the enzyme responsible for converting the toxic alcohol intermediate, acetaldehyde, into harmless acetic acid. This irreversible inhibition leads to the rapid accumulation of acetaldehyde in the blood when alcohol is consumed. The resulting high concentration of acetaldehyde triggers a severe and acutely unpleasant response, known as the Acetaldehyde Syndrome, which effectively reinforces the patient’s decision to maintain abstinence.

Regulatory References

What side effects are possible with Antinol?

Possible Side Effects and Safety Information

The safety profile of Disulfiram, the active ingredient in Antinol, is defined by the potential for a severe Disulfiram-Alcohol Reaction and officially documented adverse reactions categorized by frequency and organ system involvement.

Key Regulatory Safety Classifications

Category	Description based on Regulatory Documentation
Serious Adverse Reactions	Includes risks of Hepatic Failure (hepatotoxicity, which may be fulminant), severe peripheral and optic neuropathy, and cardiovascular events (e.g., myocardial infarction, acute heart failure) associated with the Disulfiram-Alcohol Reaction.
Frequency-Classified Effects	Common effects, often transient during the first two weeks of therapy, include headache, fatigue, drowsiness, and a metallic or garlic-like aftertaste. The frequency of certain psychiatric (e.g., psychotic reactions) and neurological effects (e.g., peripheral neuritis) is classified as Not Known in some official documents.
System-Organ-Classes	Adverse effects are documented across the Nervous System (e.g., headache, polyneuritis), Hepatobiliary (liver damage), Psychiatric (e.g., depression, paranoia), and Reproductive Systems (e.g., impotence).

Time-Related Patterns and Safety Constraints

Certain effects, such as drowsiness and headache, are noted as being typically transient during the initial two weeks of therapy. The risk of the severe Disulfiram-Alcohol Reaction persists for up to 14 days after the medicine is last administered.

Official regulatory documents stipulate that the medicine must not be administered to a patient in an intoxicated state and requires the patient's full knowledge and consent. Abstinence from all forms of alcohol is an essential constraint due to the severity of the potential reaction.

Overdose and Emergency Response

The official regulatory documents detail the required response and documented manifestations associated with an acute overdose of Antinol (Disulfiram). Documented clinical manifestations can include gastrointestinal effects such as nausea, vomiting, abdominal pain, and diarrhoea. Central Nervous System effects often include drowsiness, delirium, hallucinations, and lethargy. Acute systemic signs involve tachycardia, hyperthermia, and hypotension.

Overdose can escalate to severe or life-threatening outcomes, including convulsions, coma, and cardiovascular collapse. Due to the potential for delayed toxicity, severe neurological sequelae like encephalopathy or sensorimotor neuropathy may become evident days after the initial exposure.

Emergency medical attention is required immediately if an overdose is suspected. Regulatory guidance explicitly states to contact a Poison Control Center or seek care in an emergency room at once. Immediate emergency services must be called if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Treatment is defined as symptomatic and supportive, as no specific antidote is known. Management may include supportive measures such as gastric lavage, administering activated charcoal, and measures to counteract documented effects like hypotension. Observation is recommended following the acute event. Regulatory labeling notes that hypotonia may be a prominent finding, particularly in children.

Therapeutic Uses of Antinol

What Antinol Treats: Main Uses and Benefits

The therapeutic application of Disulfiram (Antinol) is centered on providing supportive pharmacological assistance within the structured treatment of Alcohol Use Disorder (AUD), focusing on managing the risk of relapse and contributing to the goal of abstinence. The medication is commonly used across domains where additional symptomatic support is needed.

Disulfiram is generally used for managing conditions characterized by periods of heightened symptoms related to chronic alcohol dependence and the symptom cluster of impulsive or compulsive alcohol consumption. It is utilized in clinical settings such as Medication-Assisted Treatment (MAT) and structured rehabilitation programs. This strategic support helps reinforce the patient's commitment to recovery and plays a role in managing the risk of relapse. As a supportive tool, it assists with maintaining functional stability during symptomatic phases of recovery.

“The primary goal is supporting sustained abstinence by establishing a physiological deterrent.”

Quick Fact: Relief for Recurrent Drinking Behavior

Sustaining Long-Term Abstinence

Disulfiram is generally used in patients with chronic alcoholism to support the therapeutic goal of sustained sobriety. The medication may assist in managing symptom clusters related to recurrent drinking, which helps support the patient's efforts toward sustained abstinence.

Preventing Impulsive Drinking and Relapse

The medication helps address symptom clusters related to impulsive or compulsive alcohol consumption. This strategic support helps reinforce the patient's commitment to recovery and plays a role in managing the risk of relapse.

Eligibility and Restrictions for Use

Who Can and Cannot Use Antinol (Disulfiram)?

This section outlines the officially documented patient population rules for using Disulfiram, based strictly on government regulatory labeling.

Allowed Populations and Prerequisites

The medicine is established for use in adult patients with chronic alcohol dependence who are highly motivated to maintain abstinence. Treatment initiation requires that the patient has not ingested any alcohol or alcohol-containing products for at least 12 to 24 hours prior.

Absolute Contraindications

Disulfiram must not be used in patients with known hypersensitivity to the drug or related compounds. Use is strictly prohibited for individuals with severe, uncompensated conditions, including severe myocardial disease, uncompensated heart failure, or a history of a cerebrovascular accident (stroke). It is also contraindicated in patients with manifest psychoses and advanced hepatic disease.

Age and Special Populations

Safety and effectiveness have not been established in pediatric patients (children and adolescents). For older adults (over age 60), use is generally not recommended. Furthermore, Disulfiram is contraindicated during pregnancy, and regulatory guidelines advise that it should not be used by women who are breastfeeding.

Restricted Use

Caution is required for patients with comorbidities such as renal failure, reduced hepatic function, severe pulmonary disease, or epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with other substances as officially documented in government regulatory sources, such as FDA Prescribing Information and national health agency monographs.

Interaction Classifications

Classification Type	Details
Severity Classification	Contraindicated (Alcohol, Metronidazole, Paraldehyde); Clinically Significant (Metabolic interactions requiring dose adjustment and monitoring).
Interaction Context Constraints	Phenytoin co-administration mandates baseline and subsequent serum level determination to manage increased exposure.

Official Interaction Statements

Co-administration with alcohol (including alcohol-containing preparations), Metronidazole, or Paraldehyde is strictly contraindicated.
Disulfiram decreases the rate of metabolism for drugs like Phenytoin, leading to elevated blood concentrations that require monitoring for clinical toxicity.
The product may prolong prothrombin time when co-administered with oral anticoagulants (e.g., Warfarin), indicating an interaction that necessitates management procedures.
Interaction with Isoniazid requires observation for marked changes in mental status.
A mandatory timing restriction requires individuals to avoid alcohol for at least 12 hours before starting the product, and the reaction risk persists for up to 14 days after discontinuation.

Connection to the Overall Interaction Profile

Regulatory documents define the interaction structure primarily through absolute prohibitions against specific substances that cause severe pharmacodynamic and neurological effects. The profile is further characterized by pharmacokinetic interactions resulting from enzyme inhibition, which necessitates label-mandated monitoring and dosage management procedures for co-administered drugs to manage increased systemic exposure.

Mechanism of Action

The mechanism of Disulfiram is centered on the Aldehyde Dehydrogenase enzyme system and results in a predictable and pronounced physiological consequence when alcohol is consumed.

Irreversible Blockade of Alcohol Metabolism

The drug's function begins with the irreversible inhibition of the Aldehyde Dehydrogenase (ALDH) enzyme, the key enzyme responsible for metabolizing acetaldehyde. Disulfiram's active metabolite forms a stable, covalent bond with the ALDH enzyme, permanently deactivating it. The enzyme inhibition prevents the conversion of acetaldehyde, leading to its rapid accumulation in the bloodstream.

Acetaldehyde-Driven Vascular and Autonomic Response

When acetaldehyde levels increase significantly due to ALDH inhibition, this toxic metabolite acts as a potent mediator, triggering a cascade of physiological effects. Acetaldehyde directly causes systemic vasodilation, which leads to a noticeable decrease in blood pressure (hypotension). The body compensates for this rapid vascular change with a reflexive increase in heart rate (tachycardia), alongside stimulating peripheral pathways that mediate visceral responses.

Mechanism Persistence and Constraint

Due to the irreversible nature of the enzyme bond, the physiological alteration remains active until the body can synthesize sufficient new ALDH. This mechanism is physiologically constrained, as the characteristic aversive consequences are entirely dependent on the presence of ethanol to initiate the toxic buildup.

Dosage and Administration Information

The established method of administration for Disulfiram (Antinol) is the oral route using the available tablet formulation. Administration follows a structured approach that begins only after the patient has abstained from alcohol for at least 12 hours, and it is utilized as an adjunct to supportive treatment.

Standard Labeled Dosage and Schedule

Treatment is administered once daily, typically in the morning. If a sedating effect occurs, the dose may be shifted to bedtime. The dosing regimen is generally divided into two phases:

Initial Dose: A maximum of 500 mg is given once daily for a period of one to two weeks.
Maintenance Dose: The dose is adjusted to an average of 250 mg daily, with a labeled range spanning from 125 mg to 500 mg. The daily dose must not exceed 500 mg.

If a dose is missed, the standard protocol is to take it upon remembering, but to skip the missed dose entirely if it is almost time for the next scheduled dose to avoid a double dose.

Administration Context and Duration

The tablets may be crushed and mixed with various liquids, such as water, coffee, milk, or fruit juice, to ease consumption. Administration must be continuous and uninterrupted, often required for months or years depending on the established need for support. For specific populations, caution is necessary; older adults generally initiate treatment at the lower end of the dosing range. Upon discontinuing the medication, alcohol consumption must still be avoided for a minimum of 14 days, as the physiological effect persists.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Antinol (Disulfiram)

Evidence for Use in Supporting Abstinence in Alcohol Use Disorder

The majority of Disulfiram (Antinol) research examined its study in adjunct to treatment for chronic alcohol dependence, focusing on outcomes related to continuous abstinence from alcohol. This medication was studied for use within structured programs that include counseling and behavioral therapy. The evidence base includes randomized controlled trials (RCTs), where researchers studied its use in patients with Alcohol Use Disorder.

Studies have measured outcomes related to episodic or acute changes in drinking behavior, primarily tracking the time until a patient took their first drink or until a major relapse. Research has also examined the proportion of patients who achieved continuous sobriety over the observed time intervals. Findings describe patterns observed in the studies that suggest differences in measured outcomes based on how the medication was administered. Trials where medication intake was directly supervised reported outcomes described patterns related to lower variability in time-to-first drink measurements. Conversely, studies where patients took the medication on their own, without direct supervision, sometimes reported outcomes that were mixed or showed patterns related to placebo use.

Evidence for Use in Co-occurring Substance Use Disorders

Research has also explored the role of Disulfiram in individuals facing additional challenges, specifically conditions involving periods of heightened symptoms related to both cocaine and alcohol dependence. These trials measured both alcohol-related outcomes and frequency of cocaine use, often comparing Disulfiram against a placebo or other medications. This area of research is characterized by a smaller body of evidence compared to the primary indication. The findings were mixed across different study designs and populations.

Long-Term Studies and Follow-up Data

Research has examined the durability of outcomes by utilizing different follow-up durations. Controlled trials often focus on short-term symptom changes, lasting between two and six months. However, the evidence base is supplemented by observational studies that have followed patients over long periods, which track large groups of patients. These observational studies contributed to findings on outcomes extending beyond one year, but the long-term effects are not fully established through highly controlled clinical trials lasting more than a year.

What is Still Uncertain About Antinol's Research Base

The clinical research conducted to date provides valuable context, but it also highlights areas where certainty remains low and further investigation is needed. A key issue is the difficulty in conducting truly double-blind studies because the physiological reaction to alcohol when taking Disulfiram may make it obvious to participants whether they received the active medicine or the placebo. Furthermore, evidence quality varies across studies, and many controlled trials had sample sizes that were modest or follow-up durations were limited. Specifically, long-term effects are not fully established beyond the observation periods of most controlled trials, and subgroup findings are uncertain for specific comorbidities or demographic groups. Research is ongoing to continue refining the understanding of this medication's place in the evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Antinol (FAQ)

Q: How quickly do people typically notice a change after starting Antinol?

According to official product information, the medication is absorbed slowly from the gastrointestinal tract. While the therapeutic goal is to support abstinence, the physiological effect that creates the alcohol reaction is known to persist for up to two weeks even after the last dose is taken.

Q: Is Antinol safe to take long-term, according to official sources?

Official regulatory documents describe continuous administration for months or years as common for this medication. However, official sources have reported instances of hepatic failure (severe liver damage) after long-term use. For this reason, regulatory documents require that liver function tests be monitored throughout the duration of use as a safety precaution.

Q: Is there a patient support program or official source for Antinol information?

Official patient information suggests that patients be provided with and carry a special Identification Card at all times. This card should state that the medicine is being taken and list the severe symptoms of the Disulfiram-Alcohol Reaction. It also provides space for the patient's physician or institution contact information in case of emergency.

Q: What is the standard guidance if a known side effect occurs while taking Antinol?

Guidance suggests that for common effects such as drowsiness or headache, patients should inform their healthcare professional if the symptoms become severe or do not subside. For symptoms suggesting a serious adverse reaction, such as yellowing of the skin or eyes, official guidance indicates that prompt medical evaluation is necessary.

Q: Does Antinol require a prescription in most places?

Yes, according to official drug availability information, the active ingredient Disulfiram is classified as a prescription-only medication.

Q: Does Antinol interact with common over-the-counter pain relievers?

Regulatory guidance suggests that a healthcare professional should be consulted before using any nonprescription medications. This is because some over-the-counter products, such as certain cough syrups, may contain alcohol, which is strictly forbidden while taking this medication due to the risk of a severe reaction.

Q: Is Antinol considered a standard first-line treatment for its indicated uses?

Medical resources describe this medication as a second-line option for chronic alcohol dependence. It is typically considered when other initial treatments have not been effective, or for patients who have a high motivation to maintain total abstinence.

Q: Does Antinol contain any common allergens, like gluten or soy?

Official US labeling for the product lists several inactive ingredients, including anhydrous lactose. Official guidance suggests that patients with specific concerns about allergens or known sensitivities should discuss the full list of ingredients with their healthcare provider.

Q: Can Antinol be used by people who have mild stomach sensitivity?

Official patient information notes that if the medication is administered with food, it may help to reduce the possibility of stomach upset or other mild gastrointestinal disturbances.

Q: What are the inactive ingredients in Antinol?

The official US labeling lists the following inactive ingredients: colloidal silicon dioxide, anhydrous lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, and stearic acid.

Q: Is it necessary to take Antinol with a meal?

While the tablets can be taken whole or mixed into various liquids, official patient resources note that the potential for developing stomach upset may be lessened if the dose is administered with food.

Q: What happens if a person taking Antinol develops a fever?

For new or unexpected symptoms, such as fever, the patient is generally expected to seek medical advice promptly. This is because symptoms like general discomfort (malaise) or vomiting can sometimes be signs of more serious adverse reactions, such as hepatic toxicity (liver damage).

Q: Are there any known issues with taking Antinol before or after surgery?

Official patient precautions state that if a patient is scheduled to undergo any type of surgery, including minor dental surgery, the treating doctor or dentist should be informed that the patient is currently taking the medication.

Q: Does Antinol have a generic equivalent?

Yes, a generic version of the medication containing the active ingredient Disulfiram is generally available.

Q: Is Antinol absorbed immediately, or does it build up over time?

According to regulatory documentation, the medication is absorbed slowly after ingestion from the gastrointestinal tract. It is also described as being eliminated slowly from the body.

Q: Can Antinol affect lab test results?

Regulatory documents state that monitoring various laboratory tests is necessary both before starting and throughout the course of treatment. This includes checking liver function tests and a complete blood count to detect any potential changes in the body.

How should Antinol be stored and disposed of?

How to Store and Dispose of Disulfiram (Antinol)

Disulfiram tablets must be stored at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F), according to official prescribing information. The medication must be protected from environmental factors; specifically, store it away from excess heat, moisture, and direct light. It is essential to keep from freezing and store the tablets in the container they came in, with the lid tightly closed.

All regulatory documents mandate that the product must be stored out of the sight and reach of children and pets. For disposal of unused or expired tablets, follow local requirements for pharmaceutical waste and do not flush the medication down the toilet unless expressly instructed to do so.

Antinol